期刊文献+

高效液相色谱法测定盐酸文拉法辛缓释胶囊中有关物质 被引量:3

An HPLC method for determination of related substances of venlafaxine hydrochloride sustained-release capsules
原文传递
导出
摘要 目的:建立高效液相色谱测定盐酸文拉法辛缓释胶囊有关物质的方法。方法:采用Venusil XBP C18色谱柱(250 mm×4.6 mm,5μm),流动相为乙腈-1%三乙胺溶液(取三乙胺10 mL,加水稀释至1000 mL,用磷酸调节pH至3.0)(28∶72),流速为1.0 mL·min-1,检测波长为226 nm,柱温为30℃。结果:盐酸文拉法辛与有关物质分离良好,辅料不干扰测定,线性工作曲线为Y=46.776X+0.4435,r=1.0000,最低检测限12.67 ng·mL-1,定量限为44.84 ng·mL-1,回收率为99.4%(n=9)。结论:本方法操作简便准确,灵敏度高,适用于盐酸文拉法辛缓释胶囊有关物质检查。 Objective : To establish an HPLC method for the determination of related substances of venlafaxine hydrochloride sustained-release capsules. Methods: Venusil XBP C18 column(250 mm ×4.6mm,5μm)was used and the mobile phase was composed of 1 volume of triethylamine,28 volumes of acetonitrile and 72 volumes of water adjusted to pH 3.0 with orthophosphoric acid. The flow rate was 1.0 mL·min^-1, the detection wavelength was 226 nm,and the column temperature was 30 ℃. Results:Venlafaxine hydrochloride and related substances could be baseline separated,and the excipients didn't interfere with the determination. The Delta standard curve equation was Y = 46. 776X + 0. 443 5 ( r = 1. 000 0). The detection limit was 12.67 ng·mL ^- 1, and the limit of quantification was 44.84 ng·mL ^- 1 The average recoveries were 99.4% ( n = 9). Conclusion: This method is rapid, accurate and sensitive and can be used for determination of the content and related substances of venlafaxine hydrochloride sustained-release capsules.
出处 《中国新药杂志》 CAS CSCD 北大核心 2014年第11期1311-1315,1320,共6页 Chinese Journal of New Drugs
关键词 盐酸文拉法辛缓释胶囊 高效液相色谱法 有关物质 venlafaxine hydrochloride sustained-release capsules HPLC related substances
  • 相关文献

参考文献10

二级参考文献28

共引文献9

同被引文献29

  • 1刘春玲.文拉法辛的临床应用[J].中国药业,2007,16(18):60-61. 被引量:14
  • 2GIBB A, DEEKS ED. Vortioxetine: first global approval[ J]. Drugs, 2014,74(1) :135 - 145.
  • 3CITROME L. Vortioxetine for major depressive disorder: a sys- tematic review of the efficacyand safety profile for this newly ap- proved antidepressant-what is the numberneeded to treat, number needed to harm and likelihood to be helped or harmed? [ J]. Int J Clin Pract, 2014,68( 1 ) :60 -82.
  • 4BANG-ANDERSEN B, RUHLAND T, JORGENSEN M, et al. Discovery ofl -[ 2-( 2,4-dimethylphenylsul-fanyl ) phenyl ] pipera- zine( Lu AA21004) : a novel muhimodal compound for the treat- ment of majordepressive disorder [ J ]. J Med Chem , 2011,54 (9) :3206 - 3221.
  • 5MORK A, MONTEZINHO LP, MILLER S, et al. Vortioxetine (LuAA21004), a novel muhimodal antidepressant, enhances memoryin rats [ J ]. Pharmacol Biochem Behav, 2013,105 ( Suppl C) : S41 - S50.
  • 6SANCHEZ C, PEHRSON AL, BETRY C, et al. Vortioxetine (LUaa21004), an investigational multimodal antidepressant: differ-entiation from currently used antidepressants in preclinical rodentmodels [ abstract ] [ J ]. Biol Psychiatry, 2013,73 ( 9 Suppl 1) : S106 - S107.
  • 7HADDJERI N, ETIEVANT A, PEHRSON A, et al. Effects of the muhi-modal antidepressant Lu AA21004 on rat synaptic and cellularhippocampal plasticity and memory recognition [ abstract no. P. 2. h. 002 ] [ J ]. Eur Neuropsychopharmacol, 2012,22 ( Suppl 2) :S303.
  • 8THEUNISSEN EL, STREET D, HOJER AM, et al. A random- ized trial onthe acute and steady-state effects of a new antidepres- sant, vorti-oxetine (Lu AA21004), on actual driving and cogni- tion [ J ]. Clin Pharmacol Ther, 2013,93 ( 6 ) :493 - 501.
  • 9AREBERG J, SOGAARD B, HOJER AM. The clinical pharma- cokineticsof Lu AA21004 and its major metabolite in healthy young volunteers [ J ]. Basic Clin Pharmacol Toxicol, 2012,111 (3) :198 -205.
  • 10BOULENGER JP, LOFT H, OLSEN CK. Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 rag/day: a randomized, double-blind, placebo-controlled, duloxetine-refereneed study in the acute treatment of adult patients with major depressive disor- der[ J]. Int J Clin Psychopharmacol,2014,29(3 ) :138 - 149.

引证文献3

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部